Detalhe da pesquisa
1.
Exposure assessments in reproductive and developmental toxicity testing: An IQ-DruSafe industry survey on current practices and experiences in support of exposure-based high dose selection.
Regul Toxicol Pharmacol
; 107: 104413, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31229519
2.
Analysis of exposure margins in developmental toxicity studies for detection of human teratogens.
Regul Toxicol Pharmacol
; 105: 62-68, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30981719
3.
Lack of value of juvenile animal toxicity studies for supporting the safety of pediatric oncology phase I trials.
Regul Toxicol Pharmacol
; 96: 167-177, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29763632
4.
Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
Regul Toxicol Pharmacol
; 67(3): 382-91, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24012707
5.
Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals.
Regul Toxicol Pharmacol
; 58(2): 243-51, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20558225
6.
Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat.
Int J Toxicol
; 29(1): 3-19, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-19903873
7.
On the use of juvenile animal studies to support oncology medicine development in children.
Reprod Toxicol
; 66: 128-130, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27262663
8.
Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species.
Drug Metab Lett
; 1(2): 153-61, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19356036